Transmissible Spongiform Encephalopathies Advisory Committee
February 8, 2005 Meeting
Date and Time:
The meeting will be held on February 8, 2005, 8:00 a.m. to 5:30 p.m.
Location:
: Hilton-Washington DC/Silver Spring, 8727 Colesville Road, Silver Spring, MD, 20910, 301-589-5200
Contact Persons:
William Freas, Ph.D., or Sheila D. Langford, 301-827-0314, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 3014512392. Please call the Information Line for up-to-date information on this meeting.
Agenda:
On February 8, 2005, the committee will discuss risk assessments for potential exposure to the variant Creutzfeldt-Jakob disease (vCJD) agent in plasma products. The committee will then discuss possible vCJD risk from investigational coagulation Factor XI manufactured in the 1990's from plasma of donors residing in the United Kingdom. In the afternoon the committtee will discuss potential deferral of blood and plasma donors for history of transfusion in France and other European countries.
Oral Presentations:
Between approximately 11:50 a.m. and 12:30 p.m., 3:15 and 3:35 p.m., and 4:45 and 5:00 p.m. on February 8, 2005, oral presentations from the public will be scheduled. Those desiring to make formal oral presentations should notify the contact person before February 3, 2005.
|
